GSK PLC GSK shares rose 1.78% to £13.72 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.42% to 9,061.49. GSK PLC ...

Find insight on European pharmaceutical sector corporate bonds, GSK and more in the latest Market Talks covering Health Care.

The FDA oncologic drugs advisory committee voted against the approval of GSK’s blood cancer treatment Blenrep, delivering a setback to the drugmaker’s efforts to reintroduce the drug to the U.S.

The FTSE 100 index of leading shares has broken through 9,000 for the first time. That’s not as impressive as it ...

Explore Matthews International Corporation's restructuring efforts, asset sales, and challenges in reducing debt. Click for ...

GSK PLC GSK shares advanced 3.60% to £14.84 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.37% to 8,494.85. GSK ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory uncertainties, GSK and Pfizer have decided to lay to rest their patent ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed last Friday at p1,359.00.

Moderna’s (MRNA) Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is shrinking. Read more here.

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank of America Securities reiterated a Sell ...

The bottom line is GSK scans as an intriguing buy for both value and income investors right now. That being said, its shares aren't going to yield market-crushing returns anytime soon.